Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


Long-Acting Cabotegravir for HIV Prevention

This podcast episode features an international expert panel discussion on key considerations for using long-acting cabotegravir as HIV PrEP.
person default
Yvonne Gilleece, MB BCh, BAO
Cristina Mussini, MD
Babafemi Taiwo, MBBS
Darrell H. S. Tan, MD, FRCPC, PhD
Released: September 9, 2022

In this episode, an international expert panel shares their thoughts on key considerations for incorporating long-acting cabotegravir as an additional HIV pre-exposure prophylaxis option for appropriate individuals at high risk of acquiring HIV infection.

Topics include anticipated patient interest in this new paradigm, the role of the oral lead-in phase, new guideline recommendations for monitoring during PrEP, patient care and follow-up after PrEP discontinuation, and remaining unanswered questions.

Other episodes in this 4-part series cover additional aspects of long-acting antiretrovirals for HIV treatment and prevention, including key steps for switching patients to long-acting injectable cabotegravir plus rilpivirine for HIV treatment, such as selecting the most appropriate patients, introducing patients to the long-acting option, and preparing patients for what to expect from long-acting treatment in terms of efficacy, visit timing, and the injection experience; key considerations at the operational level for incorporating long-acting injectable ART into the HIV treatment armamentarium; and what is still needed in long-acting HIV care to further address patient needs and inequities across subgroups.

Information on this Educational Activity


Babafemi Taiwo, MBBS

Gene Stollerman Professor of Medicine
Division of Infectious Diseases
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Babafemi Taiwo, MBBS: consultant/advisor/speaker: Gilead Sciences, Johnson & Johnson, ViiV Healthcare.
Yvonne Gilleece, MB BCh, BAO

Honorary Clinical Professor in HIV Medicine and Sexual Health
Department of Global Health & HIV
Brighton & Sussex Medical School
Consultant in HIV Medicine and Sexual Health
HIV Department
University Hospitals Sussex NHS Foundation Trust
Brighton, United Kingdom

Yvonne Gilleece, MB, BCh, BAO: educational meetings: ViiV; advisor: Gilead Sciences, ViiV; conference sponsorship: Gilead Sciences.
Cristina Mussini, MD

Head of Department of Infectious Diseases and Tropical Medicine
Full Professor of Infectious Diseases

Infectious Diseases Clinics, University Hospital
University of Modena and Reggio Emilia
Modena, Italy

Cristina Mussini, MD: consultant/advisor/speaker: AbbVie, Angelini, Gilead Sciences, Janssen, MSD, Pfizer, Roche, ViiV Healthcare; researcher: Gilead Sciences, Janssen, MSD, ViiV Healthcare.
Darrell H. S. Tan, MD, FRCPC, PhD

Associate Professor
Division of Infectious Diseases
University of Toronto
Division of Infectious Diseases
St. Michael's Hospital
Toronto, Canada

Darrell H. S. Tan, MD, FRCPC, PhD: researcher: AbbVie, Gilead Sciences, GlaxoSmithKline.

Program Medium

This program has been made available online.


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
ViiV Healthcare

Related Content

Dr Milosz Parczewski discusses HIV Glasgow 2022 reports on the impact of the war in Ukraine on HIV care in Eastern Europe, from Clinical Care Options (CCO)

Milosz Parczewski, MD, PhD Released: November 22, 2022

Expert discussion of data reported at IDWeek 2022 on serologic response to the HepB-CpG vaccine in people with HIV, from Clinical Care Options (CCO)

Joseph J. Eron, Jr., MD Released: November 22, 2022

Expert selections of cutting-edge HIV data, including the latest on long-acting therapies and pre-exposure prophylaxis.

Jeffrey Kwong, DNP, MPH, FAANP, FAAN Released: November 22, 2022

Clinical Care Options (CCO) presents expert faculty discussing new data from AIDS 2022, from nursing perspectives

Joseph J. Eron, Jr., MD
Program Director
Jeffrey Kwong, DNP, MPH, FAANP, FAAN
Program Director
Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Program Director
person default Allison Webel, PhD, RN Mitchell J. Wharton, PhD, RN, FNP-BC, CNS, ACRN
Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: November 22, 2022 Expired: November 21, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings